# Manal F. Abdelmalek

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/manal-f-abdelmalek/

## Facts

| Field | Value |
| --- | --- |
| Citations | 46,406 |
| Field | Liver Disease Diagnosis and Treatment |
| h-index | 92 |
| i10-index | 187 |
| Last Known Institution | Mayo Clinic |
| OpenAlex ID | https://openalex.org/A5011069724 |
| ORCID iD | https://orcid.org/0000-0002-5001-8618 |
| Works | 355 |

## Researcher papers

- [MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease](https://scholariq.org/papers/mafld-a-consensus-driven-proposed-nomenclature-for-metabolic-associated-fatty/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease-3/)
- [A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis](https://scholariq.org/papers/a-phase-3-randomized-controlled-trial-of-resmetirom-in-nash-with-liver-fibrosis/)
- [Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial](https://scholariq.org/papers/obeticholic-acid-for-the-treatment-of-non-alcoholic-steatohepatitis-interim/)
- [Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening](https://scholariq.org/papers/elafibranor-an-agonist-of-the-peroxisome-proliferator-activated-receptor-and/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease-2/)
- [A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH](https://scholariq.org/papers/a-randomized-controlled-trial-of-the-pan-ppar-agonist-lanifibranor-in-nash/)
- [High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase](https://scholariq.org/papers/high-fat-and-high-sucrose-western-diet-induces-steatohepatitis-that-is-dependent/)

## Researcher topics

- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Liver Disease and Transplantation](https://scholariq.org/topics/liver-disease-and-transplantation/)
- [Diet, Metabolism, and Disease](https://scholariq.org/topics/diet-metabolism-and-disease/)
- [Liver Diseases and Immunity](https://scholariq.org/topics/liver-diseases-and-immunity/)
- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)

## Researcher university

- [Mayo Clinic](https://scholariq.org/institutions/mayo-clinic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.